Guiding diagnosis, prognosis, and therapy options
Our comprehensive test menu includes testing to aid in providing both diagnostic and prognostic information, and in treatment selection across the full spectrum of malignancies. Each assay is developed and validated in collaboration with Mayo Clinic oncologists, pathologists, and laboratorians. Through our clinical experience and expertise, we strive to provide testing options that improve patient care, increase efficiency, and reduce costs.
Stay up-to-date on the latest discoveries and test launches. Sign up for our monthly oncology newsletter.
Additional test offerings
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
genetic tests developed for solid tumors
areas of specialized oncology testing
specializing in molecular and
cytogenetic diagnostic testing
support from Mayo Clinic physicians and scientists
Diagnostic, prognostic, and predictive testing
Our comprehensive menu offers testing to provide diagnostic and prognostic information and helps guide treatment selection across the full spectrum of malignancies. Our tumor-specific panels only include genes that are clinically proven to impact patient outcomes. This eliminates confusing results, decreases the cost of testing, and leads to better patient care.
Integration of clinical care, pathology, genetics, and bioinformatics
We take the lead in designing and optimizing testing to guide patient care based on specific tumors. Our experience with clinical care is integrated with our expertise in pathology, genetics, and bioinformatics to direct which genes are selected for each panel and how these panels are used in a clinical setting.
not just results
Genetic testing is about more than just determining whether a mutation is present or not. We take complex genetic results and turn them into clinically actionable answers. Our clinicians, laboratorians, and genetic counselors are available 24/7 to provide expertise and consultative support, eliminating the guesswork from results interpretation.
Webinar: Practical Aspects and Pitfalls of the Molecular Diagnosis of Brain Tumors
This “Specialty Testing” webinar will address practical aspects and pitfalls in the molecular diagnosis of brain tumors. All molecular testing platforms have factors that impact testing in the pre-analytical, analytical, and post-analytical phases. These factors will be discussed during the presentation and highlighted through clinical cases to illustrate the pitfalls in brain tumor molecular diagnosis encountered in the clinical practice at Mayo Clinic.
This week's Research Roundup feature: A stress-induced cilium-to-PML-NB route drives senescence initiation.
As someone affected by chronic liver disease, Susan Parrott knows how it feels to live in uncertainty. But every few months, the anxiety and doubt that shadow her life fade when Mayo Clinic Laboratories test results confirm her condition is in check and she can continue living life on her own terms.
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
For Billy Dowell Jr., a competitive golfer, focus, determination, and course correction are essential to excelling at the sport. These skills, along with routine follow-up care and testing, are also important to navigating a life impacted by multiple chronic autoimmune conditions.